Abstract
Angiogenin is a member of the ribonuclease superfamily that is associated with the angiogenic process. Angiogenesis is regarded as an important step to support primary and metastatic tumor growth. In cutaneous T cell lymphoma (CTCL), angiogenesis in lesional skin is increased, suggesting that interaction between tumor cells and their microvasculature are likely to occur during progression of CTCL. Patients with hematological malignancies show increased serum angiogenin levels, which are related with poor overall survival. To investigate possible roles of angiogenin in development of CTCL, we measured serum angiogenin levels in 36 patients with CTCL and 21 healthy controls by enzyme-linked immunosorbent assay. We also investigated angiogenin mRNA and protein expression in lesional skin of CTCL by quantitative RT-PCR and immunohistochemistry. Serum angiogenin levels in patients with CTCL were significantly higher than those in healthy controls. When classified with types of skin lesions, serum angiogenin levels were elevated only in erythrodermic CTCL patients. Angiogenin mRNA expression levels in lesional skin were significantly elevated in erythrodermic CTCL compared to normal skin. Immunohistochemical study revealed that angiogenin was expressed by keratinocytes, endothelial cells, and infiltrating lymphocytes in CTCL. Our results suggest that enhanced angiogenin expression may be related with a poor prognosis of erythrodermic CTCL. As angiogenin acts as an inhibitor of polymorphonuclear leukocyte degranulation, angiogenin may also be linked to impaired host defense in erythrodermic CTCL.
Abbreviations
- CTCL:
-
Cutaneous T cell lymphoma
- MF:
-
Mycosis fungoides
- mRNA:
-
Messenger RNA
- SS:
-
Sézary syndrome
References
Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, Robson A, Calonje E, Stefanato CM, Wain EM, Wilkins B, Fields PA, Dean A, Webb K, Scarisbrick J, Morris S, Whittaker SJ (2010) Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 28:4730–4739
Alexandrakis MG, Passam FH, Pappa CA, Sfiridaki K, Tsirakis G, Damilakis J, Stathopoulos EN, Kyriakou DS (2005) Relation between bone marrow angiogenesis and serum levels of angiogenin in patients with myelodysplastic syndromes. Leuk Res 29:41–46
Axelrod PI, Lorber B, Vonderheid EC (1992) Infections complicating mycosis fungoides and Sézary syndrome. JAMA 267:1354–1358
Brunner B, Gunsilius E, Schumacher P, Zwierzina H, Gastl G, Stauder R (2002) Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia. J Haematother Stem Cell Res 11:119–125
Fett JW, Strydom DJ, Lobb RR, Alderman EM, Bethune JL, Riordan JF, Vallee BL (1985) Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry 24:5480–5486
Fang S, Repo H, Joensuu H, Orpana A, Salven P (2011) High serum angiogenin at diagnosis predicts for failure on long-term treatment response and for poor overall survival in non-Hodgkin lymphoma. Eur J Cancer 47:1708–1716
Folkman J, Klagsbrun M (1987) Angiogenic factors. Science 235:442–447
Hartmann A, Kunz M, Köstlin S, Gillitzer R, Toksoy A, Bröcker EB, Klein CE (1999) Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. Cancer Res 59:1578–1583
Houge G, Døskeland SO (1996) Divergence towards a dead end? Cleavage of the divergent domains of ribosomal RNA in apoptosis. Experientia 52:963–967
Hu G, Riordan JF, Vallee BL (1994) Angiogenin promotes invasiveness of cultured endothelial cells by stimulation of cell-associated proteolytic activities. Proc Natl Acad Sci USA 91:12096–12100
Hu GF, Riordan JF (1993) Angiogenin enhances actin acceleration of plasminogen activation. Biochem Biophys Res Commun 197:682–687
Krejsgaard T, Vetter-Kauczok CS, Woetmann A, Lovato P, Labuda T, Eriksen KW, Zhang Q, Becker JC, Ødum N (2006) Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia 20:1759–1766
Lyons RM, Gentry LE, Purchio AF, Moses HL (1990) Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol 110:1361–1367
Mazur G, Woźniak Z, Wróbel T, Maj J, Kuliczkowski K (2004) Increased angiogenesis in cutaneous T-cell lymphomas. Pathol Oncol Res 10:34–36
Moenner M, Gusse M, Hatzi E, Badet J (1994) The widespread expression of angiogenin in different human cells suggests a biological function not only related to angiogenesis. Eur J Biochem 226:483–490
Musolino C, Alonci A, Bellomo G, Loteta B, Quartarone E, Gangemi D, Massara E, Calabrò L (2004) Levels of soluble angiogenin in chronic myeloid malignancies: clinical implications. Eur J Haematol 72:416–419
Rendl M, Mayer C, Weninger W, Tschachler E (2001) Topically applied lactic acid increases spontaneous secretion of vascular endothelial growth factor by human reconstructed epidermis. Br J Dermatol 145:3–9
Rybak SM, Fett JW, Yao QZ, Vallee BL (1987) Angiogenin mRNA in human tumor and normal cells. Biochem Biophys Res Commun 146:1240–1248
Sugaya M, Fang L, Cardones AR, Kakinuma T, Jaber SH, Blauvelt A, Hwang ST (2006) Oncostatin M enhances CCL21 expression by microvascular endothelial cells and increases the efficiency of dendritic cell trafficking to lymph nodes. J Immunol 177:7665–7672
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2008) WHO classification of tumors of haematopoietic and lymphoid tissues, 4th edn. IARC Press, Lyon
Tello-Montoliu A, Patel JV, Lip GY (2006) Angiogenin: a review of the pathophysiology and potential clinical applications. J Thromb Haemost 4:1864–1874
Tschesche H, Kopp C, Hörl WH, Hempelmann U (1994) Inhibition of degranulation of polymorphonuclear leukocytes by angiogenin and its tryptic fragment. J Biol Chem 269:30274–30280
Vacca A, Moretti S, Ribatti D, Pellegrino A, Pimpinelli N, Bianchi B, Bonifazi E, Ria R, Serio G, Dammacco F (1997) Progression of mycosis fungoides is associated with changes in angiogenesis and expression of the matrix metalloproteinases 2 and 9. Eur J Cancer 33:1685–1692
Verstovsek S, Kantarjian H, Aguayo A, Manshouri T, Freireich E, Keating M, Estey E, Albitar M (2001) Significance of angiogenin plasma concentrations in patients with acute myeloid leukaemia and advanced myelodysplastic syndrome. Br J Haematol 114:290–295
Vihinen P, Kallioinen M, Vuoristo MS, Ivaska J, Syrjänen KJ, Hahka-Kemppinen M, Kellokumpu-Lehtinen PL, Pyrhönen SO (2007) Serum angiogenin levels predict treatment response in patients with stage IV melanoma. Clin Exp Metastasis 24:567–574
Acknowledgments
We thank Tamami Kaga for technical assistance. These studies were supported by grants from the Ministry of Education, Culture, Sports and Technology.
Conflict of interest
The authors state no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Miyagaki, T., Sugaya, M., Suga, H. et al. Angiogenin levels are increased in lesional skin and sera in patients with erythrodermic cutaneous T cell lymphoma. Arch Dermatol Res 304, 401–406 (2012). https://doi.org/10.1007/s00403-012-1238-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00403-012-1238-0